Kongshan Ci Completes Series A Funding: Full-Stack Brain-Computer Neural Regulation Platform Leads New Paradigm in Psychiatric Diagnosis and Treatment | TongNews

Background

Recently, Dalton Venture portfolio company KoSyne NeuroTech, a Shanghai-based company focused on next-generation brain-computer interface and neuroregulation technology, announced the completion of its Series A funding round. The round was led by Oriental Fortune Capital, with Yaotu Capital participating, while existing investors Dalton Venture and Yunqi Capital continued to increase their stakes. The proceeds will be primarily used for product R&D iteration, medical device registration, and global expansion.

The following article is reprinted from VBData.

Author: Chen Maoyu

Hundreds of millions of people worldwide suffering from depression, anxiety, obsessive-compulsive disorder, Alzheimer's disease, and other psychiatric and cognitive disorders are waiting for a more effective, precise, and accessible treatment solution. The traditional "one-size-fits-all" approach is being rapidly disrupted, yet no company globally has established a full-stack ecosystem spanning from underlying technology to clinical application in the multi-energy neuroregulation赛道.

KoSyne NeuroTech is confronting this complexity head-on — rejecting standardized, cookie-cutter treatments and committing to reading each unique brain map through precise brain-computer interface technology, providing optimal solutions and exceptional product experiences that exceed expectations for every individual trapped by mental illness.

01

A globally leading system architecture of "whole-brain functional connectivity computing engine + robotic navigation + multi-modal closed-loop regulation"

Stemming from deep insight into psychiatric and cognitive disorders, KoSyne NeuroTech has firmly embedded itself at the clinical front lines, seeking optimal solutions for every specific scenario. Based on this, the company has developed a globally leading brain-computer interface neuroregulation architecture combining "whole-brain functional connectivity computing engine + robotic navigation + multi-modal closed-loop regulation." This architecture uses the "whole-brain functional connectivity computing engine" and "robotic navigation" as foundational supports, integrating understanding of magnetic, ultrasound, electrical, and other energy modalities to achieve full-chain intelligence from signal perception, target computation, precise execution, to closed-loop regulation.

Built upon this globally leading architecture, KoSyne NeuroTech has self-developed transcranial focused ultrasound, navigated transcranial magnetic stimulation systems, and closed-loop electrical stimulation as flexibly deployable technology platforms, precisely stripping away unnecessary technical interference and retaining only the most efficient intervention pathways. This "problem-solving-centered" research accumulation enables KoSyne NeuroTech to truly provide individualized, effective systematic solutions for patients with different indications — one of the company's core competitive moats.

02

Three pipelines with scarce full-scenario brain-computer interface neuroregulation capabilities, achieving internationally leading clinical outcomes

Facing enormous clinical demand, KoSyne NeuroTech has established a clear three-stage implementation path: driving cutting-edge technology validation through high-level scientific research collaboration, establishing medical standards through rigorous clinical evidence, and simultaneously developing home treatment devices. The company has built a product matrix covering in-hospital treatment for psychiatric and cognitive disorders, as well as home treatment for emotional and sleep disorders.

Focused ultrasound can precisely reach deep brain nuclei, acting on the thalamus, amygdala, hippocampus, anterior cingulate cortex, and other key brain regions governing emotion, cognition, and pain. However, skull attenuation and deflection of sound waves has long been a global technical challenge. At the transcranial focused ultrasound system level, KoSyne NeuroTech is successively launching 64 to 1024-channel self-developed transcranial focused ultrasound systems. Through built-in phase control engines, the system completes waveform correction based on each patient's skull anatomical characteristics, overcoming energy attenuation and focal point deviation when sound waves penetrate the skull, enabling millimeter-level precision直达 deep brain regions with dynamic focal point adjustment, successfully transforming highly manual-experience-dependent research-grade acoustic experiments into stable, safe routine clinical diagnostic and treatment methods.

At the navigated transcranial magnetic stimulation system level, KoSyne NeuroTech's navigated transcranial magnetic stimulation system is the company's first Class III medical device to enter registration clinical trials, providing a new precise treatment option for depression patients. Currently, the system has initiated the highest-specification clinical validation in China's neuroregulation field — with Beijing Anding Hospital, Shanghai Mental Health Center, Xiangya Second Hospital, and Huaxi Hospital, four national psychiatric centers, conducting clinical enrollment simultaneously for the first time, demonstrating strong clinical demand and high recognition.

At the closed-loop electrical stimulation product level, the team leverages temporal interference electrical stimulation technology, achieving precise targeting through self-developed transformation of deep electric field complex physical model algorithms, equipped with independently operating real-time EEG signal analysis modules, thereby realizing spatiotemporally precise closed-loop electrical stimulation intervention solutions. KoSyne NeuroTech's closed-loop electrical stimulation product will serve as the critical bridge from in-hospital intensive treatment to out-of-hospital long-term management, constructing a full-lifecycle psychiatric and cognitive disorder management closed loop.

03

In China for Global: KoSyne NeuroTech will lead the global paradigm shift in psychiatric and cognitive disease diagnosis and treatment with high-quality Chinese innovation

KoSyne NeuroTech was founded by a senior interdisciplinary team, with core members covering the full chain of capabilities including neuroscience, acoustic engineering, medical imaging, artificial intelligence, robotics, and medical device registration. This team combines academic depth, industry experience, and global vision, serving as the core force leading the transformation of global psychiatric and cognitive disease diagnosis and treatment.

KoSyne NeuroTech has established scientific research and clinical cooperation networks with several renowned overseas universities and top medical institutions, and plans to simultaneously initiate FDA and CE registration, taking the China-validated precise neuroregulation model to North American, European, and Southeast Asian markets, allowing innovation originating from China to serve hundreds of millions of psychiatric and cognitive disease patients globally.

KoSyne NeuroTech deeply believes that the understanding and enhancement of emotion and cognition is humanity's ultimate need — and also the core piece of the puzzle leading to general intelligence. Every product iteration at KoSyne NeuroTech advances toward the same mission: decoding emotion, understanding cognitive changes, and ultimately establishing a precise, warm, and sustainable regulatory bond between brain function and machine, responding to humanity's eternal desire for understanding and being understood through technological innovation.

Dalton Venture stated: We are optimistic about the potential of non-invasive brain-computer interfaces and non-invasive neuroregulation technology across numerous application scenarios. The KoSyne NeuroTech team possesses exceptional execution capability, balancing technological innovation and commercial translation, steadily advancing three pipelines while clearly laying out global scientific research cooperation. We will continue to support the company and are optimistic about its growth into an influential brand enterprise.

END

ID: daltonventure

Long press to follow

Recommended Reading